Cancer is an important cause of mortality in children. In the 1-14 year age group it comes second only to accidents as a cause of death. There have been many changes in the management of both leukaemias and solid tumours in the past 30 years. Many of these have been reported, together with results, in the form of clinical trials. Nearly all such trials however require some degree of selection of cases and very little information is available on the survival rates of unselected series of patients, particularly for the most recent years. One large study has been published on childhood cancer survival in Great Britain (Draper et al., 1982) , but only includes children who were diagnosed before 1975. Another series from the United States included only white children from the years (Myers et al., 1975) . The present study examines the trends in survival rates of childhood cancer in Queensland during the 25 year period from 1956 to 1980.
Methods
Information on cases was obtained from the Queensland Childhood Malignancy Registry (McWhirter & Bacon, 1981) . This is a population based registry which includes all children with malignant tumours and also all intracranial tumours who were under the age of 15 years and resident in Queensland at the date of incidence. Although registration is believed to be complete from 1973 Group C (1973-76) contained 252 patients, and Group D (1977-80) 275 patients. Survival data was examined using standard methods of life table analysis (Peto et al., 1977) . The P values in Table V are based on 3 degrees of freedom for heterogeneity ( Nevertheless the x2 values for both heterogeneity and trend are highly significant (Table V) . Stratification by diagnostic group made no appreciable difference; the corresponding values for x2 after stratification were 64.4 and 54.7. The greatest improvement in survival occurred in acute lymphoblastic leukaemia (ALL). The 5-year survival rate increased from 2.2% in Group A to 6.6% in Group B (Figure 1 ) and to 45% in Group C, but only to 48% in Group D (Figure 2 ). x2 for Group C versus Group D = 0.14, P> 0.7. Significant trends in survival rates over the 4 groups were also seen in non-Hodgkin's lymphoma, Hodgkin's disease, Wilms' tumour, medulloblastoma, retinoblastoma and bone tumours (Table V) (Draper et al., 1982; Myers et al., 1975) . The survival rates quoted in these two series may be compared with those in Tables III and IV , and are generally of the same order as those for the present series (see Table VI ).
The most important advance, in terms of reduction of overall cancer mortality, has been the increase in the survival rate for ALL. Before 1970 this disease was almost invariably fatal. Almost half the children in Group C survived 5 years from the time of diagnosis, but there was virtually no further gain in survival for those in Group D. The development of carefully planned chemotherapy including multiple drug induction and consolidation regimes, CNS prophylaxis with combined cranial radiation and intrathecal chemotherapy, and better supportive care such as vigorous treatment of actual and potential infection have all contributed to the improvement. For acute non-lymphoblastic leukaemia (ANLL), there has been a considerable increase in the proportion of children attaining an initial remission, but the subsequent relapse rate remains high (Wilbur et al., 1981) . As a result, there are still very few long-term survivors.
The introduction of effective chemotherapy, with or without radiotherapy, for non-Hodgkin's lymphoma (Wollner et al., 1976) has greatly improved long-term survival in this condition, and most children who are alive at 4 years from diagnosis are likely to be cured of their disease (Anderson et al., 1983) . Current methods of treatment for Hodgkin's disease, including combined chemotherapy and extended field radiotherapy are now producing extremely high cure rates, probably accompanied by less morbidity than was seen with older methods of treatment (Jenkin & Berry, 1980) . Despite numerous attempts to improve the prognosis for neuroblastoma, long term results have remained disappointing, especially in older children who tend to have advanced disease at the time of diagnosis. In contrast with the results which might have been expected from the literature on the use of chemotherapy in rhabdomyosarcoma (Bizer, 1980) , there was no significant improvement in the survival rates for this tumour. The number of cases is, however, small. This together with the fact that the different histological criteria may have been applied during the 25 year period must cast slight doubt on the accuracy of the survival rates in Groups A and B. The use of chemotherapy with agents such as vincristine, dactinomycin, and cyclophosphamide has reduced the need for radical surgery, especially in embryonal rhabdomyosarcoma, so that the long term morbidity in the survivors is probably less than previously.
There has been a substantial improvement in the survival rate for Wilms' tumour. This is in keeping with published results (D'Angio et al., 1981) and reflects the universal use of chemotherapy, especially vincristine and dactinomycin, in this tumour. The application of radiotherapy has also been refined, and it is now clear that radiotherapy is not required in cases where the disease is confined to the kidney (D'Angio et al., 1981) . Amongst the brain tumours there is a mixed picture dependent on the morphological diagnosis. There is an obvious difference in the survival pattern between juvenile astrocytomas of low malignancy and the anaplastic variety. This has been noted previously (Draper et al., 1982; Bloom, 1982a) , and confirms the value of accurate histological diagnosis. In neither type was a significant trend in survival rates observed. Unlike the astrocytomas, there has been a significant improvement in survival for medulloblastoma. Changes in radiotherapy techniques have led to higher cure rates for this tumour (Berry et al., 1981) , and adjuvant chemotherapy may be resulting in further improvement, with 5-year survival rates of -70% being reported (Bloom, 1982b) . Some of the patients with medulloblastoma in Group D received various forms of chemotherapy in addition to surgery and radiotherapy. Although some of the patients with ependymoma also received chemotherapy, it is not yet possible to assess the effect of this because of the relative rarity of this tumour. In general, the patients with brain stem glioma were treated by radiotherapy alone and the results were extremely poor. Although there were some long-term survivors in Groups A and B, the longest survival amongst Groups C and D was 26 months.
The outlook in retinoblastoma was good in the later 3 groups and survival rates were similar to those in Britain (Draper et al., 1982) . The survival rates for bone tumours appear quite high in Groups C and D. Comparison with other series is however difficult since the pattern of incidence is quite different from that in other reported series, Ewing's tumour being much commoner than osteosarcoma in Queensland (McWhirter & Bacon, 1981) . The reason for this is not known. In histiocytosis X, there appears to have been some improvement in survival, but the trend was not statistically significant, perhaps because of the small numbers. The possibility also exists that in Group B there may have been some under-ascertainment of cases of localised disease (eosinophilic granuloma), so that the true survival rate for this period may have been higher than Table III would  indicate. Clinical trials almost invariably involve some initial selection of patients depending on the presence or absence of various clinical or laboratory features. Some patients or their parents may refuse consent to be entered into a trial, or an individual case may be judged unsuitable for one reason or another. Additionally, patients may be excluded later from the trial because of relapse, violation of protocol, or an ill-defined reason such as "non-evaluability". A population-based study of survival therefore gives a more realistic assessment of current survival rates and the changes which have occurred over a period of time. The results of this study indicate that the outlook for children with cancer improved considerably around the late 1960s or early 1970s. Relatively little further improvement has occurred in the later 1970s. Over the 25 year period significant improvement occurred in the survival rates of ALL, nonHodgkin's lymphoma, Hodgkin's disease, Wilms' tumour, medulloblastoma, and retinoblastoma. The results of treatment of some tumours such as neuroblastoma, anaplastic astrocytoma, and brain stem glioma remain poor, while ALL is still an important cause of death in children. There is therefore a need for continuing research into the treatment of childhood cancer, in the hope of producing better results in this latter group. The results of clinical trials in some selected groups of patients should give no cause for complacency.
